Anti-cancer medicine made by Huangpu company enters Chinese market

BeiGene announces that it has started sales of its tislelizumab injection as a prescription drug since March 5.

BeiGene, a biopharmaceutical company in Huangpu, has announced that it has started sales of its tislelizumab injection as a prescription drug since March 5.

Cancer patients from more than 160 cities in China have been able to purchase and use the high quality tislelizumab injection locally.

The company, which is a pioneer in medicine research and development, has focused on developing molecularly targeted and immuno-oncology drug candidates for the treatment of cancer.

Its tislelizumab injection is the first tumor immunotherapy medicine in the world developed by BeiGene and is also the first independently owned anti-cancer medicine of BeiGene's that has been approved to enter the Chinese market.

The medicine has been used as a monotherapy in pivotal phase 2 clinical trials in relapsed/refractory classical Hodgkin's lymphoma (R/R cHL), second-line urothelial carcinoma, and second- or third-line hepatocellular carcinoma (HCC).

Currently, the tislelizumab injection has carried out 15 registered or potentially registered clinical trials in 23 countries and regions around the world, while six of them are carried out in international centers, involving more than 5,000 patients with cancers of high incidence, such as lung cancer, liver cancer, esophageal squamous cell carcinoma, and stomach cancer.

The commercial supply of the tislelizumab injection has been entrusted to Boehringer Ingelheim, a German company with a profound history and abundant experience.

The production base for BeiGene in Guangzhou, adhering to the standards of GMP (Good Manufacturing Practice) in China, the United States, and the Europe, has finished the construction of its first phase.

The first phase of the base has achieved a production capacity of 8,000 liters, and the whole capacity is expected to reach 50,000 liters in the future, offering steady supply of the tislelizumab injection.

Share - WeChat